President, Oncology

Associate Director, Statistical Programming

Corcept to Present New Late-Breaking Data From Pivotal ROSELLA Trial of Relacorilant in Platinum-Resistant Ovarian Cancer at ESMO 2025

Corcept Can't Escape Teva's Mifepristone Antitrust Suit

Corcept Therapeutics Insider Sold Shares Worth $2,821,033, According to a Recent SEC Filing

FDA Files Corcept’s New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer

Key Accounts Manager

Corcept Therapeutics is a leader in the research and development of cortisol modulators, aiming to transform the treatment of serious diseases. The Key Accounts Manager will develop and execute strategies to drive disease awareness and enhance partnerships within targeted healthcare systems, focusing on hypercortisolism and related diseases.

Key Accounts Manager, Northeast

Associate Director, Talent Acquisition

Senior Director Human Resources

Vice President, Market Access, Oncology

Key Account Manager

Sign up with Google

Sign in with Google